Table of Contents
- Why medical device launch prioritization is harder than it looks
- What medtech portfolio management actually requires
- How OnePlan supports global product launch sequencing
- How Advaiya implements OnePlan for medtech device launches
- Stop arguing about priorities and start defending them
- Frequently asked questions
A typical medtech portfolio carries more launch programs than the organization can fund, staff, and clear through regulators in any given year. Some programs target the US under a 510(k) pathway. Others sit behind the queues for EU MDR Notified Bodies. A few pace reviews with China’s NMPA while planning Japan PMDA submissions a year later. Each program competes for the same scarce people: regulatory specialists, clinical evaluators, manufacturing transfer leads, and commercial planners.
Most companies still coordinate these decisions in spreadsheets and quarterly steering committees. Spreadsheets do not fail because of formatting; the failure is structural. A spreadsheet cannot model what happens when you advance program A and defer program B, or when a Notified Body audit slips by ten weeks. The decision becomes political, the portfolio drifts, and OnePlan exists to remove that drift.
Why medical device launch prioritization is harder than it looks
Medtech launch decisions carry more dependencies than most product launches. Each device has a distinct regulatory pathway, manufacturing route, and reimbursement story by country. A device that is Class II in the US may be Class III under EU MDR. CE marking through a Notified Body assessment commonly takes longer than a US 510(k) for a similar device, so a product greenlit in one market can sit in the queue elsewhere while competitors take share.
The FDA’s Quality Management System Regulation became effective on February 2, 2026, aligning 21 CFR Part 820 with ISO 13485:2016. Manufacturers running concurrent launches now have to keep design history files, supplier audit records, and validation evidence inspection-ready across every program. Portfolio managers who cannot see those compliance dependencies at the portfolio level get surprised, and surprises in medtech are expensive.
The deeper problem is that launch prioritization is still treated as a once-a-year exercise. Markets do not move once a year. A competitor’s clearance, a change in reimbursement codes, a supply shock, or a Notified Body bottleneck can invalidate last quarter’s plan within weeks. Portfolios that cannot re-rank in real time fund work that no longer makes commercial sense.
What medtech portfolio management actually requires
Portfolio management for medtech is less about Gantt charts and more about deciding what not to do. A workable system has to do three things consistently, every quarter, without descending into committee theatre.
Scoring each launch on commercial and clinical evidence
A medtech portfolio scoring model has to weight more than projected revenue. Clinical evidence strength, reimbursement coverage in target markets, regulatory pathway clarity, manufacturing readiness, and KOL engagement all belong in the model. Pure financial scoring rewards optimistic forecasts and ignores the slower indicators of whether a launch will land.
Sequencing markets, not launching everywhere at once
Most medtech companies that struggle with global launches are trying to do too much at once. Staggered submissions, pursuing one anchor market first, learning from the review cycle, then filing in adjacent geographies with a harmonized technical file, almost always outperform parallel-everywhere strategies on cost and timeline. The discipline is in saying no to markets two and three until market one is on a clear track.
Modeling resource demand against actual capacity
Regulatory writers, clinical leads, validation engineers, and manufacturing transfer specialists are shared across programs. A portfolio view that does not flag capacity conflicts before they happen produces late launches. Resource demand modeling is the most underused capability in medtech PPM, and the one that pays back the fastest.
How OnePlan supports global product launch sequencing
OnePlan is a strategic portfolio and work management platform built on Microsoft Cloud. Forrester named it a Strong Performer in the Wave for Strategic Portfolio Management, Q2 2024, with the highest possible scores in integration and roadmap criteria. Microsoft has named OnePlan its PPM Partner of the Year for five consecutive years. For medtech leaders, three capabilities matter most.
Scenario modeling for launch sequencing decisions
Scenario modeling lets a launch committee compare actual portfolio configurations. What happens to addressable revenue if you defer an NMPA filing by six months and reallocate two regulatory specialists to the EU MDR program? If a Notified Body assessment slips by ten weeks, how does that affect the cardiology launch in Germany? OnePlan answers in minutes instead of weeks.
Resource demand planning across regulatory programs
OnePlan surfaces capacity constraints across specialized roles before they become timeline failures. A medtech firm cannot keep two extra regulatory writers idle on the bench. Knowing in advance which programs will compete for the same person lets the portfolio team sequence work rather than overcommit and miss dates.
Financial planning by market and SKU
Launch costs vary widely by country. Clinical evaluation under EU MDR adds meaningful per-class spend. Reimbursement code applications, KOL training, and post-market surveillance commitments all carry country-specific budgets. OnePlan tracks forecasts and actuals against capital plans by market, giving CFOs and BU heads the spend visibility that quarterly reviews used to bury.
How Advaiya implements OnePlan for medtech device launches
OnePlan is a platform. What makes it work for a medtech portfolio is the implementation. Advaiya is a Microsoft Solutions Partner across five designations, and we focus on connecting OnePlan to the way medtech teams actually decide what to launch, when, and where.
Our project portfolio management framework integrates OnePlan with Power BI dashboards, Microsoft Project schedules, and SharePoint document control. For organizations familiar with strategic portfolio management in life sciences, the medtech application looks similar but moves on faster cycles. The same enterprise architecture discipline we apply to portfolio decisions in pharma R&D and manufacturing compliance under GxP translates directly to medtech launch governance.
When Advaiya unified CRM systems for a Fortune 500 industrial manufacturer, we migrated more than one million records across 60+ countries with a 65% reduction in data redundancy. Cleaning what is broken before configuring what is new separates a working OnePlan deployment from a stalled one.
Stop arguing about priorities and start defending them
If your launch committee is still debating sequence in quarterly meetings while competitors clear regulators ahead of you, the problem is not the people. The problem is the decision environment. Talk to our team about how a properly configured OnePlan implementation can put your global launch sequence on visible, defensible ground.
Frequently asked questions
Medtech portfolio management is the discipline of selecting, sequencing, and resourcing every active device program against commercial, clinical, regulatory, and operational criteria. Project management runs each launch; portfolio management decides which launches get funded, accelerated, deferred, or terminated.
OnePlan tracks milestones by regulatory stage for each market, connecting FDA 510(k) or PMA pathways, EU MDR submissions, PMDA filings, and NMPA reviews to resource and financial plans. The platform does not replace a regulatory information management system; instead, it connects regulatory milestones to portfolio decisions.
Phased implementations deliver initial portfolio visibility within 8 to 12 weeks. Full enterprise rollouts with financial and resource integration typically take 4 to 6 months.
Yes. OnePlan integrates natively with Microsoft Project, Azure DevOps, Power BI, SharePoint, and Dynamics 365, and connects to PLM and QMS systems through APIs.
Project management runs individual launch programs from regulatory filing through commercial rollout. Portfolio management decides which launches to fund, how to sequence them, and how to allocate scarce talent across the pipeline.
OnePlan tracks post-market study commitments, periodic safety reports, and supplier audit obligations as milestone-gated programs, showing which surveillance work competes for the same resources as upcoming launches.
